In summary, the therapeutic use of this antihistamine with calcitriol could be beneficial as adjuvant therapy for BC, independently of the tumor phenotype, since the molecular targets of these compounds are the VDR and EAG1 channel, both of them highly expressed in BC. Here, KCNH1 is linked to breast cancer.